Table 3.
Antimicrobial susceptibility of Clostridium difficile piglet isolates and human clinical isolates.
| Piglet |
Humanc |
||||||||
|---|---|---|---|---|---|---|---|---|---|
| MIC (μg/mL) |
MIC (μg/mL) |
No. of resistant isolates (n = 100) | MIC (μg/mL) |
No. of resistant isolates (n = 73) | |||||
| Antimicrobials | Break point | 50% | 90% | Range | 50% | 90% | Range | ||
| Vancomycin | ≥32a | 1 | 2 | 1–4 | 0 | 0.5 | 1 | 0.06–2 | 0 |
| Metronidazole | ≥32b | 0.5 | 8 | 0.125–8 | 0 | 0.25 | 0.25 | <0.06–0.25 | 0 |
| Clindamycin | ≥8b | 8 | 256 | 0.25–>256 | 59 (59.0%) | 256 | >256 | 0.125–>256 | 64 (87.7%) |
| Ceftriaxone | ≥64b | 16 | 32 | 2–>256 | 6 (6.0%) | 256 | 256 | 0.125–>256 | 62 (84.9%) |
| Erythromycin | ≥8a | 2 | >256 | 1–>256 | 46 (46.0%) | >256 | >256 | <0.125–>256 | 61 (83.6%) |
| Ciprofloxacin | ≥4a | 8 | 8 | 0.5–128 | 75 (75.0%) | 64 | 64 | 0.125–64 | 68 (93.2%) |
MIC, minimum inhibitory concentration.
aThe value was the previous report break point (Oka et al., 2012).
bThe value was the CLSI break point (Clinical Laboratory Standards Institute [CLSI], 2007).
cThese isolates were isolated in the previous report Oka et al. (2012).